Deep B cell depletion is delivering transformative clinical results in autoimmune diseases. Dealmakers are wagering on the best tools for the job.
References
-
Marshall, A. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02955-8 (2025).
-
Gong, Q. et al. J. Immunol. https://doi.org/10.4049/jimmunol.174.2.817 (2005).
-
Wang, Q. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2509522 (2025).
-
Xu, J. et al. Lancet https://doi.org/10.1016/S0140-6736(25)01030-X (2025).
-
Bucci, L. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2506740 (2025).
-
Reshef, R. et al. Transplant. Cell. Ther. https://doi.org/10.1016/j.jtct.2025.12.014 (2026).
-
Bar, N. et al. Leukemia https://doi.org/10.1038/s41375-025-02841-x (2026).
-
Tariq, A. et al. Ann. Int. Med. https://doi.org/10.7326/ANNALS-25-04559 (2026).
-
Kuai, R. et al. Adv. Ther. https://doi.org/10.1002/adtp.202000094 (2020).
-
Banik, S. M. et al. Nature https://doi.org/10.1038/s41586-020-2545-9 (2020).
-
Song, Y., Zhou, B., Long, J. & Peng, Y. J. J. Autoimmun. https://doi.org/10.1016/j.jaut.2025.103475 (2025).
-
Zhang, L. et al. JCI Insight https://doi.org/10.1172/jci.insight.172914 (2023).
Ethics declarations
Competing interests
R.G.-B. has research support or honoraria from AbbVie, Alfasigma, AstraZeneca, Bristol Myers Squibb, Candid Therapeutics, Cullinan Therapeutics, Epana Bio, Gilead, Kite, Johnson & Johnson, Kyverna Therapeutics, Lilly, Novartis, Pfizer, Sanofi, Xencor and UCB.
Rights and permissions
About this article
Cite this article
Senior, M., Grieshaber-Bouyer, R. B cell depletion in autoimmune disease: in vivo CAR-T or T cell engagers?. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03069-5
-
Published:
-
Version of record:
-
DOI: https://doi.org/10.1038/s41587-026-03069-5